About this episode
On this episode of Fat Science , Dr. Emily Cooper, Andrea Taylor and Mark Wright delve deeper into the topic of compounded metabolic drugs. Dr. Cooper addresses criticisms from listeners about the previous discussion and provides insights into the economic reasons driving people towards compounded drugs. She also dissects the ethics and economics of the diet industry transforming into a subscription medicine model and the role of insurance in accessibility to metabolic treatments. Key Takeaways: Compounded drugs often act as a misleading alternative to brand medications, lacking FDA approval and potentially jeopardizing health outcomes. Employers significantly influence weight-related treatment coverage, and advocacy for coverage changes can be a crucial step towards accessible medications. Insurance restrictions and economic barriers force many to explore compounded drugs despite potential risks. The rise of online subscription models parallels the diet industry’s modus operandi of exploiting vulnerable demographics for profit. Greater transparency and regulation within the pharmaceutical and insurance sectors are needed to ensure safe and equitable access to treatments. Personal Stories & Practical Advice: Andrea reflects on her decision to prioritize health despite the significant cost by sourcing medications through Canada rather than risking compounded drugs. Discussions emphasize the importance of a comprehensive and guided medical approach, advocating for patient education and active engagement with healthcare providers. Important Update: Changes in GLP-1 Medication Availability and Compounding Regulations This episode was recorded before recent regulatory developments regarding GLP-1 medications. As of our current information: The FDA has determined that shortages have been resolved for all formulations of tirzepatide (marketed as Mounjaro and Zepbound) and semaglutide (marketed as Rybelsus, Ozempic, and Wegovy). Consequently, compounding these medications is no longer legally permitted under FDA regulations. Additionally, Novo Nordisk has expanded its patient assistance program by implementing enhanced coupon discounts across all Wegovy dosage strengths to improve affordability and access to match Lilly's efforts for Mounjaro and Zepbound access. Please note that regulatory policies and manufacturer programs regarding these medications continue to evolve. For the most up-to-date information, we recommend consulting current FDA announcements and manufacturer websites. Resources: Connect with Dr. Emily Cooper on LinkedIn. Connect with Mark Wright on LinkedIn . Connect with Andrea Taylor on Instagram . Fat Science is a podcast on a mission to explain where our fat really comes from and why it won’t go and stay away. We are committed to creating a world where people are empowered with accurate information about metabolism and recognize that fat isn’t a failure. This podcast is for informational purposes only and is not intended to replace professional medical advice. If you have a question for Dr. Cooper, a show idea, feedback, or just want to connect, email us at info@diabesityinstitute.org . Fat Science is supported by the non-profit Diabesity Institute which is on a mission to increase access to effective, science-based medical care for those suffering from or at risk for diabesity. https://diabesityresearchfoundation.org/